Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.09
$0.040.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 70.08% | -37.71% | -61.80% | -- |
| Gross Profit | -- | -70.08% | 37.71% | -122.43% | -- |
| SG&A Expenses | -20.45% | -10.86% | -34.59% | -42.75% | -33.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -222.93% | -- |
| Total Operating Expenses | -20.91% | -22.12% | -34.58% | -59.27% | -50.84% |
| Operating Income | 20.91% | 22.12% | 34.58% | -163.29% | 51.20% |
| Income Before Tax | 199.33% | 54.96% | -24.43% | -170.61% | 53.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 199.33% | 54.96% | -24.43% | -170.61% | 53.77% |
| Earnings from Discontinued Operations | -- | 100.00% | 2,144.32% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 181.43% | 62.09% | 285.51% | -170.61% | 43.61% |
| EBIT | 20.91% | 22.12% | 34.58% | -163.29% | 51.20% |
| EBITDA | 20.44% | 21.59% | 35.28% | -158.62% | 52.47% |
| EPS Basic | 168.35% | 71.21% | 255.91% | -159.52% | 51.42% |
| Normalized Basic EPS | 50.26% | 104.55% | -4.57% | -159.52% | 60.28% |
| EPS Diluted | 168.26% | 70.25% | 255.79% | -161.11% | 51.42% |
| Normalized Diluted EPS | 50.33% | 104.55% | -4.57% | -160.51% | 60.28% |
| Average Basic Shares Outstanding | 19.14% | 31.66% | 18.99% | 18.64% | 16.08% |
| Average Diluted Shares Outstanding | 19.30% | 31.66% | 18.99% | 16.69% | 16.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |